All News

Found 99 articles

• 

  BioSpace Movers and Shakers: March 8

  3/8/2019

  Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.

• Industry Central Nervous System Specialist Lee Dawson, Ph.D. Joins Cerevance as VP of Neuroscience

  3/5/2019

  Dawson to help lead the pursuit of neuronal and glial targets revealed by cell-type-specific profiling of thousands of post-mortem human brain samples

• Datacubed Health Names Leaders in Neurology, Genomics, Internal Medicine, Rare Disease and Psychiatry to Science Advisor Panel

  2/11/2019

  Datacubed Health today announced the appointment of its new Science Advisor Panel, consisting of world-renowned scientists and technologists spanning a wide and diverse range of fields.

• Dementia Discovery Fund launches new research accelerator partnership with the UK Dementia Research Institute at inaugural Annual Forum for Dementia

  10/23/2018

  ​D3A will support important research projects with potential to create meaningful new medicines for dementia

• Cerevance Appoints Ted Hibben as Chief Business Officer

  10/9/2018

  Cerevance today announced that it has appointed Ted Hibben as Chief Business Officer.

• Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease

  9/25/2018

  Cerevance today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.

• Former Inogen CEO, Ray Huggenberger, Joins Ebb Therapeutics Board of Directors

  9/18/2018

  Ebb Therapeutics announces that its added Ray Huggenberger to its Board of Directors.

• Ebb Therapeutics Appoints Elise Wilfinger as Chief Marketing Officer

  7/11/2018

  Ebb Therapeutics, announced today the appointment of Elise Wilfinger as its Chief Marketing Officer.

• Cerevance Kicks Off 2018 with Additional $10 Million of Infusions

  2/21/2018

  Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.

• Cerevance Appoints David H. Margolin, MD, PhD as Senior Vice President of Clinical and Translational Medicine

  11/27/2017

  Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period.

• Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, MD, PhD, to Advise Cerevance

  10/24/2017

  Cerevance announced that Jeremy Nathans, M.D., Ph.D., has joined the company as a senior-level scientific advisor.

• Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University

  10/17/2017

  Cerevance today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue.

• Harvard’s Rudolph Tanzi, Ph.D., A Leader In Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board

  10/12/2017

• Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., To Advise Cerevance

  10/5/2017

• Former Respironics Execs' New Startup Ebb Therapeutics to Hire at New HQ

  6/22/2017

• Global Genes To Convene RARE Partnering And Investor Forum To Accelerate Drug Development For Rare Diseases

  5/22/2017

• Dementia Discovery Fund To Invest $5 Million In Cerevance To Seek New Treatments For Dementia

  5/3/2017

• Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster

  12/2/2016

• Masimo Corporation Expands Its Board Of Directors With Appointment Of Medical Device Executive Craig Reynolds

  4/4/2014